Fact CheckerSign in

NCT07124611Recruiting

A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer

Testing the Feasibility of Incorporating Psychosocial Oncology During Neoadjuvant Therapy for Patients With Pancreatic Cancer

Source: ClinicalTrials.gov · Last updated 19 Feb 2026

Brief summary (registry, in English)

This clinical trial tests how well a psychosocial oncology intervention during neoadjuvant therapy works for patients with pancreatic cancer that has not spread to other parts of the body (localized). Chemotherapy and/or radiation therapy is often recommended prior to surgeryf or patients with pancreatic cancer; this is known as neoadjuvant therapy (NT). The primary advantages of NT include: reducing the size of the cancer mass and/or reducing the spread of cancer, to improve the likelihood of getting all the cancer during surgery, and because receiving chemotherapy after pancreas surgery can be challenging. Other research has shown that NT can lead to improved survival and a lower rate of the cancer returning. Despite these positive effects, NT can be associated with significant physical and emotional side effects. To prepare patients for future surgery and maintain health during chemotherapy and/or radiation, prehabilitation is often recommended. This can include nutritional and physical therapy to help with physical health. An oncology (cancer) psychosocial intervention during NT may be feasible and helpful to patients with localized pancreatic cancer.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
60 (estimated)
First submitted
8 Aug 2025
Start date
22 Dec 2025
Primary completion date
31 Dec 2026
Lead sponsor
Ohio State University Comprehensive Cancer Center
NCT number
NCT07124611

What you commit to

  • Study type: Interventional
  • Planned participants: 60
  • From 22 Dec 2025 to the primary completion date, 31 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients unlikely to undergo surgical resection following NT based on anatomical or performance status considerations
  • Already received ≥ 2 cycles of chemotherapy

Other illness

  • Confirmed or presumed metastatic disease

Other

  • Prisoners
  • Persons unable to provide consent

Who the study is looking for

  • Adults ≥ 18 years of age
  • Patient:
    • Newly diagnosed patients with localized pancreatic ductal adenocarcinoma (PDAC) presenting to Ohio State University Wexner Medical Center-Comprehensive Cancer Center (OSUMC-CCC)
    • Plans to initiate neoadjuvant therapy prior to surgical resection
    • Neoadjuvant therapy (NT) and/or surgery may occur at another facility

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Ohio State University Comprehensive Cancer Center
Coordinator of this site? Confirm its status
ColumbusUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.